Saturday, 19 November 2011
Sunday, 30 January 2011
Yahoo
beauty in new your
Beauty Salon
1345 Amsterdam Ave, New York, NY
(212) 280-1846
Beauty Salon
700 W 172nd St, New York, NY
(212) 795-7108
Beauty Salon
193 Schermerhorn St, Brooklyn, NY
(718) 855-2125
Myrna Unisex Hairstyles
245 E 77th St, New York, NY
(212) 288-8381
Giovanni Sacchi Hair Salon
1364 Lexington Ave, New York, NY
(212) 360-5557
2 & 1 Hair Salon
139 E Broadway, New York, NY
(212) 227-8858
A R Hair Salon
304 8th Ave, New York, NY
(212) 206-0268
Bon Bon Hair
571 3rd Ave, New York, NY
(212) 286-2266
Kakaboka
39 W 32nd St, New York, NY
(212) 268-0688
Gil Ferrer Salon
21 E 74th St, New York, NY
(212) 535-3543
Thursday, 13 January 2011
Two medicines call for high blood pressure
A blend of drugs is far better than just one 1 in treating hypertension, a UK research has suggested. etzashoha havalalazman netotmoto
The research in the Lancet concerned 1,200 individuals and observed commencing treatment with two drugs gave far better and quicker results, with fewer negative effects.
The method challenges standard medical practice where doctors give a patient 1 drug, then add an additional later if blood stress stays higher.
Virtually ten million individuals in the UK have hypertension.
Treatment with anti-hypertensive drugs is known to reduce the risk of stroke and heart disease.
A team led by researchers in the College of Cambridge, College of Glasgow and College of Dundee followed 1,254 patients with hypertension in ten nations.
They compared the effects of giving 1 drug (both aliskiren or amlodipine) or perhaps a blend of the two.
Patients given the blend of drugs had a 25% far better response during the initial six months compared with people on standard treatment, the research observed.
This equates to a six.5mm Hg increased reduction in systolic blood stress.
Participants had been also more unlikely to quit taking their medication on account of negative effects.
The two drugs may be given being a single pill, creating it less complicated for patients to take.
Professor Morris Brown of the College of Cambridge explained the research "breaks the mould for treating hypertension".
He explained: "Most patients can now be prescribed just one blend pill and understand that they are optimally safeguarded from strokes and heart attacks."
The British Heart Foundation, which can be funding follow-up investigation, explained very good control of blood stress is difficult to attain in many patients.
Associate medical director Professor Jeremy Pearson explained: "This research adds drastically to your evidence that commencing treatment for patients with hypertension with two medicines as opposed to 1 is secure, and much more effective than waiting to add the 2nd medicine later."
The investigation was funded by the pharmaceutical organization Novartis, which helps make amlodipine and aliskiren.
The blend pill was authorized by the FDA for use in the US very last year
The research in the Lancet concerned 1,200 individuals and observed commencing treatment with two drugs gave far better and quicker results, with fewer negative effects.
The method challenges standard medical practice where doctors give a patient 1 drug, then add an additional later if blood stress stays higher.
Virtually ten million individuals in the UK have hypertension.
Treatment with anti-hypertensive drugs is known to reduce the risk of stroke and heart disease.
A team led by researchers in the College of Cambridge, College of Glasgow and College of Dundee followed 1,254 patients with hypertension in ten nations.
They compared the effects of giving 1 drug (both aliskiren or amlodipine) or perhaps a blend of the two.
Patients given the blend of drugs had a 25% far better response during the initial six months compared with people on standard treatment, the research observed.
This equates to a six.5mm Hg increased reduction in systolic blood stress.
Participants had been also more unlikely to quit taking their medication on account of negative effects.
The two drugs may be given being a single pill, creating it less complicated for patients to take.
Professor Morris Brown of the College of Cambridge explained the research "breaks the mould for treating hypertension".
He explained: "Most patients can now be prescribed just one blend pill and understand that they are optimally safeguarded from strokes and heart attacks."
The British Heart Foundation, which can be funding follow-up investigation, explained very good control of blood stress is difficult to attain in many patients.
Associate medical director Professor Jeremy Pearson explained: "This research adds drastically to your evidence that commencing treatment for patients with hypertension with two medicines as opposed to 1 is secure, and much more effective than waiting to add the 2nd medicine later."
The investigation was funded by the pharmaceutical organization Novartis, which helps make amlodipine and aliskiren.
The blend pill was authorized by the FDA for use in the US very last year
Room tourism jet operate continues
The European challenge to create a space jet for fare-paying passengers is still very considerably alive, says EADS Astrium.
article kabalashel
The aircraft, which would make short hops previously mentioned the environment, was introduced in 2007 after which practically right away put on hold due to the global downturn.
But Astrium, Europe's largest space company, says internal advancement work continues and it is going to spend a further 10m euros (£9m) on the principle in 2011.
"We hold the investment heading," mentioned Astrium CEO François Auque.
"We proceed to mature the principle, preserving the minimal crew, in order that when we locate the relevant partnership we are ready and also have progressed sufficiently," he advised reporters on Wednesday with the company's rocket manufacturing facility at Les Mureaux just north of Paris.
The Astrium automobile would be regarding the dimension of a company jet and would get off from a normal runway, using normal aircraft engines to climb to about 12km. It might then ignite a liquid oxygen-methane rocket to push the automobile to about 100km.
At this altitude, the five passengers onboard could knowledge some minutes of weightlessness just before strapping on their own back again in their seats for your return flight to the ground.
Astrium has done significant work previously on the Romeo rocket engine that might electrical power the climb to space, and wind tunnel testing has verified the aerodynamic shape.
What's presently lacking is the investment of a partner that might move the challenge from principle to production.
"As you know, we had discussions within the Gulf just before there was a change within the financial situation. Now we now have other discussions in other areas of the globe and I am quite optimistic," mentioned Mr Auque.
Far more advanced is British billionaire Sir Richard Branson's Virgin Galactic challenge. This will use an American rocket aircraft formulated by California's Scaled Composites company to deliver fare-paying passengers on sub-orbital trips.
Enterprise, as this rocket aircraft is known, is previously built and conducting glide checks. It is anticipated Enterprise will fire its rocket motor and make demonstration flights previously mentioned the environment later this year.
Mr Auque was speaking with the yearly New 12 months press conference of the European Aeronautic Defence and Space (EADS) group. In addition to owning the Astrium satellite and rocket problem, EADS also owns the airline manufacturer Airbus.
article kabalashel
The aircraft, which would make short hops previously mentioned the environment, was introduced in 2007 after which practically right away put on hold due to the global downturn.
But Astrium, Europe's largest space company, says internal advancement work continues and it is going to spend a further 10m euros (£9m) on the principle in 2011.
"We hold the investment heading," mentioned Astrium CEO François Auque.
"We proceed to mature the principle, preserving the minimal crew, in order that when we locate the relevant partnership we are ready and also have progressed sufficiently," he advised reporters on Wednesday with the company's rocket manufacturing facility at Les Mureaux just north of Paris.
The Astrium automobile would be regarding the dimension of a company jet and would get off from a normal runway, using normal aircraft engines to climb to about 12km. It might then ignite a liquid oxygen-methane rocket to push the automobile to about 100km.
At this altitude, the five passengers onboard could knowledge some minutes of weightlessness just before strapping on their own back again in their seats for your return flight to the ground.
Astrium has done significant work previously on the Romeo rocket engine that might electrical power the climb to space, and wind tunnel testing has verified the aerodynamic shape.
What's presently lacking is the investment of a partner that might move the challenge from principle to production.
"As you know, we had discussions within the Gulf just before there was a change within the financial situation. Now we now have other discussions in other areas of the globe and I am quite optimistic," mentioned Mr Auque.
Far more advanced is British billionaire Sir Richard Branson's Virgin Galactic challenge. This will use an American rocket aircraft formulated by California's Scaled Composites company to deliver fare-paying passengers on sub-orbital trips.
Enterprise, as this rocket aircraft is known, is previously built and conducting glide checks. It is anticipated Enterprise will fire its rocket motor and make demonstration flights previously mentioned the environment later this year.
Mr Auque was speaking with the yearly New 12 months press conference of the European Aeronautic Defence and Space (EADS) group. In addition to owning the Astrium satellite and rocket problem, EADS also owns the airline manufacturer Airbus.
Monday, 10 January 2011
Prozac raises stroke recuperation period
Giving stroke patients Prozac quickly soon after the occasion could aid their recovery from paralysis, a research has discovered.
Researchers discovered far more improvement in motion and larger independence soon after 3 months in patients taking the antidepressant (also referred to as fluoxetine), compared to placebo.
The Lancet Neurology research was determined by analysis on 118 patients in France.
UK stroke experts stated the findings had been "promising".
This was the biggest research of selective serotonin re-uptake inhibitors (SSRIs) and stroke recovery to date.
Tests on stroke patients ninety days soon after getting offered the drug discovered that patients taking fluoxetine had acquired drastically far more perform in their upper and lower limbs than patients who weren't offered the drug.
Individuals within the fluoxetine group had been also far more more likely to be coping independently.
All patients within the research had reasonable to severe motor disabilities subsequent their stroke.
'Dual benefit?'
The research noted that the side-effects through the antidepressant had been usually mild and infrequent, despite the fact that this group did discover far more cases of nausea and diarrhoea.
The authors, led by Professor François Chollet, stated: "The constructive effect of the drug on motor perform of recovering patients suggests that the... action of SSRIs supplies a brand new pathway that really should be explored additional within the remedy of acute ischaemic stroke."
Each year within the UK 150,000 people today possess a stroke plus a 3rd of these will be left that has a disability for instance paralysis down 1 side of their system.
Dr Sharlin Ahmed, analysis liaison officer at the UK Stroke Association, stated: "We are continually looking for new treatments which can strengthen the outcomes for stroke survivors as well as the results of this analysis look promising.
"Antidepressants, for instance fluoxetine, may be applied to treat stroke patients with depression which is a prevalent side effect of stroke, so it really is really exciting to view that this previously licensed drug could possess a dual benefit.
"However, additional analysis wants to become undertaken just before the usage of this antidepressant may be accepted as an efficient remedy for improving motion subsequent a stroke."
Researchers discovered far more improvement in motion and larger independence soon after 3 months in patients taking the antidepressant (also referred to as fluoxetine), compared to placebo.
The Lancet Neurology research was determined by analysis on 118 patients in France.
UK stroke experts stated the findings had been "promising".
This was the biggest research of selective serotonin re-uptake inhibitors (SSRIs) and stroke recovery to date.
Tests on stroke patients ninety days soon after getting offered the drug discovered that patients taking fluoxetine had acquired drastically far more perform in their upper and lower limbs than patients who weren't offered the drug.
Individuals within the fluoxetine group had been also far more more likely to be coping independently.
All patients within the research had reasonable to severe motor disabilities subsequent their stroke.
'Dual benefit?'
The research noted that the side-effects through the antidepressant had been usually mild and infrequent, despite the fact that this group did discover far more cases of nausea and diarrhoea.
The authors, led by Professor François Chollet, stated: "The constructive effect of the drug on motor perform of recovering patients suggests that the... action of SSRIs supplies a brand new pathway that really should be explored additional within the remedy of acute ischaemic stroke."
Each year within the UK 150,000 people today possess a stroke plus a 3rd of these will be left that has a disability for instance paralysis down 1 side of their system.
Dr Sharlin Ahmed, analysis liaison officer at the UK Stroke Association, stated: "We are continually looking for new treatments which can strengthen the outcomes for stroke survivors as well as the results of this analysis look promising.
"Antidepressants, for instance fluoxetine, may be applied to treat stroke patients with depression which is a prevalent side effect of stroke, so it really is really exciting to view that this previously licensed drug could possess a dual benefit.
"However, additional analysis wants to become undertaken just before the usage of this antidepressant may be accepted as an efficient remedy for improving motion subsequent a stroke."
Subscribe to:
Posts (Atom)